Biocept, Inc.
BIOC
$2.05
-$0.11-5.09%
Weiss Ratings | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.00 | |||
Price History | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -58.50% | |||
30-Day Total Return | -80.82% | |||
60-Day Total Return | -85.17% | |||
90-Day Total Return | -88.56% | |||
Year to Date Total Return | -87.58% | |||
1-Year Total Return | -95.05% | |||
2-Year Total Return | -98.44% | |||
3-Year Total Return | -98.40% | |||
5-Year Total Return | -99.89% | |||
52-Week High % Change | -95.47% | |||
52-Week Low % Change | 8.54% | |||
Price | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $47.70 | |||
52-Week Low Price | $1.99 | |||
52-Week Low Price (Date) | May 31, 2023 | |||
52-Week High Price (Date) | Jun 07, 2022 | |||
Valuation | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | $3.17M | |||
Enterprise Value | 7.98M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -64.21 | |||
Earnings Per Share Growth | 338.34% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 0.19 | |||
Price/Book (Q) | 0.53 | |||
Enterprise Value/Revenue (TTM) | 1.21 | |||
Price | $2.05 | |||
Enterprise Value/EBITDA (TTM) | -0.23 | |||
Enterprise Value/EBIT | -0.22 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 587.400K | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 858 320 8200 | |||
Address | 9955 Mesa Rim Road San Diego, CA 92121 | |||
Website | biocept.com | |||
Country | United States | |||
Year Founded | 1997 | |||
Profitability | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -552.29% | |||
Profit Margin | -553.64% | |||
Management Effectiveness | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -53.53% | |||
Return on Equity | -- | |||
Income Statement | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | $6.59M | |||
Total Revenue (TTM) | $6.59M | |||
Revenue Per Share | $11.21 | |||
Gross Profit (TTM) | -$14.55M | |||
EBITDA (TTM) | -$34.66M | |||
EBIT (TTM) | -$36.37M | |||
Net Income (TTM) | -$36.46M | |||
Net Income Avl. to Common (TTM) | -$36.46M | |||
Total Revenue Growth (Q YOY) | -96.63% | |||
Earnings Growth (Q YOY) | -223.26% | |||
EPS Diluted (TTM) | -$64.21 | |||
EPS Diluted Growth (Q YOY) | -212.60% | |||
Balance Sheet | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | $6.77M | |||
Cash Per Share (Q) | $11.53 | |||
Total Current Assets (Q) | $9.09M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | $2.43M | |||
Current Ratio (Q) | 2.070 | |||
Book Value Per Share (Q) | $4.10 | |||
Total Assets (Q) | $22.99M | |||
Total Current Liabilities (Q) | $4.39M | |||
Total Debt (Q) | $11.58M | |||
Total Liabilities (Q) | $20.57M | |||
Total Common Equity (Q) | $2.43M | |||
Cash Flow | BIOC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -$800.00K | |||
Cash from Financing (TTM) | -$1.44M | |||
Net Change in Cash (TTM) | -$20.79M | |||
Levered Free Cash Flow (TTM) | -$13.14M | |||
Cash from Operations (TTM) | -$18.55M | |||